{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:39:35Z","timestamp":1790419175711,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ijid.2020.05.085","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T11:35:20Z","timestamp":1590752120000},"page":"7-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"special_numbering":"C","title":["Lack of antiviral activity of darunavir against SARS-CoV-2"],"prefix":"10.1016","volume":"97","author":[{"given":"Sandra","family":"De Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa","family":"Bojkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindrich","family":"Cinatl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Buyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marnix","family":"Van Loock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Woodfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ciesek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ijid.2020.05.085_bib0005","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMe2005477","article-title":"Covid-19 \u2014 the search for effective therapy","volume":"382","author":"Baden","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2020.05.085_bib0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2332-7","article-title":"SARS-CoV-2 infected host cell proteomics reveal potential therapy targets, [Under review]","author":"Bojkova","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ijid.2020.05.085_bib0015","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e328345ee95","article-title":"Week 48 analysis of once-daily vs. twice-daily darunavir\/ritonavir in treatment-experienced HIV-1-infected patients","volume":"25","author":"Cahn","year":"2011","journal-title":"AIDS"},{"issue":"19","key":"10.1016\/j.ijid.2020.05.085_bib0020","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2020.05.085_bib0025","doi-asserted-by":"crossref","unstructured":"Chang Y-C, Tung Y-A, Lee K-H, Chen T-F, Hsiao Y-C, Chang H-C, et al. Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase docking. Preprints (www.preprints.org) 2020. https:\/\/doi.org\/10.20944\/preprints202002.0242.v1.","DOI":"10.20944\/preprints202002.0242.v1"},{"issue":"3","key":"10.1016\/j.ijid.2020.05.085_bib0030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.ijid.2020.05.085_bib0035","series-title":"Identification of FDA approved drugs targeting COVID-19 virus by structure-based drug repositioning","author":"Farag","year":"2020"},{"key":"10.1016\/j.ijid.2020.05.085_bib0040","unstructured":"Haitao Y, Zihe R. 2020. Available at Shanghai Institute of Materia Medica. http:\/\/www.simm.ac.cn\/xwzx\/kydt\/202001\/t20200125_5494417.html."},{"issue":"13","key":"10.1016\/j.ijid.2020.05.085_bib0045","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1056\/NEJMc2001899","article-title":"Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China","volume":"382","author":"Hoehl","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ijid.2020.05.085_bib0050","doi-asserted-by":"crossref","first-page":"12012","DOI":"10.1128\/JVI.78.21.12012-12021.2004","article-title":"Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor","volume":"78","author":"King","year":"2004","journal-title":"J Virol"},{"issue":"January","key":"10.1016\/j.ijid.2020.05.085_bib0055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.12688\/f1000research.22211.2","article-title":"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China","volume":"9","author":"Kruse","year":"2020","journal-title":"F1000Research"},{"issue":"10224","key":"10.1016\/j.ijid.2020.05.085_bib0060","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2020.05.085_bib0065","first-page":"175","article-title":"Profile of once-daily darunavir\/cobicistat fixed-dose combination for the treatment of HIV\/AIDS","volume":"8","author":"Navarro","year":"2016","journal-title":"HIV AIDS (Auckl)"},{"issue":"1","key":"10.1016\/j.ijid.2020.05.085_bib0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1468-1293.2012.01060.x","article-title":"Final 192-week efficacy and safety of once-daily darunavir\/ritonavir compared with lopinavir\/ritonavir in HIV-1-infected treatment-na\u00efve patients in the ARTEMIS trial","volume":"14","author":"Orkin","year":"2013","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2020.05.085_bib0075","unstructured":"Prezcobix prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/205395s001lbl.pdf. [Accessed 27 March 2020]."},{"key":"10.1016\/j.ijid.2020.05.085_bib0080","unstructured":"Rezolsta Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rezolsta-epar-product-information_en.pdf. [Accessed 27 March 2020]."},{"key":"10.1016\/j.ijid.2020.05.085_bib0085","article-title":"Insight derived from molecular docking and molecular dynamics simulations into the binding interactions between HIV-1 protease inhibitors and SARS-CoV-2 3CLpro","author":"Sang","year":"2020","journal-title":"ChemRxiv"},{"key":"10.1016\/j.ijid.2020.05.085_bib0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1742-6405-11-39","article-title":"Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial","volume":"11","author":"Tashima","year":"2014","journal-title":"AIDS Res Ther"},{"issue":"3","key":"10.1016\/j.ijid.2020.05.085_bib0095","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"5","key":"10.1016\/j.ijid.2020.05.085_bib0100","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm Sin B"},{"issue":"8","key":"10.1016\/j.ijid.2020.05.085_bib0105","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220303921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220303921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:51:00Z","timestamp":1761119460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971220303921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":21,"alternative-id":["S1201971220303921"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2020.05.085","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.04.03.20052548","asserted-by":"object"}]},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of antiviral activity of darunavir against SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2020.05.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}